Male breast cancer: An update in diagnosis, treatment and molecular profiling

Onami, Susan; Ozaki, Melanie; Mortimer, Joanne; Pal, Sumanta K.

doi:10.1016/j.maturitas.2010.01.012

Cited by 51 publications

(48 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most frequent histological diagnosis was invasive ductal carcinoma (IDC) in >85% as compared to (85-95%) rate of IDC in the literature (Dnami et al, 2011).…”

Section: Discussionmentioning

confidence: 91%

Clinicopathologic Characteristics of Male Breast Cancer: A Report of 21 Cases in Radiotherapy Center of Hamedan, Iran

Sedighi¹,

Hamed²,

Mohammadian³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The most frequent histological diagnosis was invasive ductal carcinoma (IDC) in >85% as compared to (85-95%) rate of IDC in the literature (Dnami et al, 2011).…”

Section: Discussionmentioning

confidence: 91%

Clinicopathologic Characteristics of Male Breast Cancer: A Report of 21 Cases in Radiotherapy Center of Hamedan, Iran

Sedighi¹,

Hamed²,

Mohammadian³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…OALib Journal breast cancer may be higher (30% -56%) [45], while others report rates of HER-2 overexpression lower (2% -18%) [46] [47]. According to Park et al [48], out of 10 Korean patients with breast cancers, five (50%) demonstrated HER-2 overexpression.…”

Section: /17mentioning

confidence: 99%

Male Breast Cancer: Case Studies and Literature Review

Zaied¹,

Khechine²,

Abbess³

et al. 2017

OALib

View full text Add to dashboard Cite

Male breast cancer is a rare disease. In Tunisia, it represents 1% of all breast cancers and 1.6% of Male neoplasia. This work is a retrospective study about 5 male patients with breast cancer, treated in the department of medical oncology at Fattouma Bourguiba University Hospital of Monastir (Tunisia) during a period of 3 years from March 2013 to March 2016. Results showed that: invasive ductual carcinoma was the histological type found in all cases; the Her 2 neu was not overexpressed in all cases; hormone receptors were positive in all patients. Two patients had a locally advanced disease. Two patients were diagnosed with metastatic disease; pulmonary and bone metastases. Three patients who were diagnosed with no metastatic disease have had a mastectomy with Axillary lymph node dissection. Adjuvant chemotherapy was administered in two patients. Loco regional radiotherapy was performed in three patients. Tamoxifen-based hormone therapy was administered in three patients. Two patients were treated with palliative chemotherapy. One patient received two lines of chemotherapy with a global survival of 16 months, while the other received only one line of palliative chemotherapy with a global survival of 2 months. One patient received palliative hormone therapy type Tamoxifen with progression free survival of 7 months. Three patients who received curative treatments are in remission of their disease. To conclude male breast cancer is a rare disease with multiple and varied risk factors. It is similar in its clinical, histological and prognostic characteristics to breast cancer in women but also has different characteristics.

show abstract

“…Male breast cancer has a higher (over 90%) hormone receptor expression and, as a consequence, reacts more effectively to endocrine therapy [6,16,17,19,22,23,24,25,26,27].…”

Section: Abstract: Male Breast Cancer Basal Markers Mesenchymal Mamentioning

confidence: 99%

“…Besides, the prognosis for male breast cancer is worse [5,18,20,21]. A study by Baojiang et al of 5-year survival rates of patients suffering from male breast carcinoma and female breast carcinoma produced the following results: 61.2% and 68.7% (DFS), and 75.% and 82.9% (OS), respectively [20].Male breast cancer has a higher (over 90%) hormone receptor expression and, as a consequence, reacts more effectively to endocrine therapy [6,16,17,19,22,23,24,25,26,27].The treatment of male breast carcinoma is based on standard methods, more specifically surgical procedures [6, 21, 25, …”

mentioning

confidence: 99%

The biological markers and results of treatment in male breast cancer patients. The Cracow experience.

Sas-Korczyńska¹,

Niemiec²,

Harazin-Lechowska³

et al. 2014

neo

View full text Add to dashboard Cite

Male breast cancer is a rare form of carcinoma with an incidence rate of approximately 0.5-1% compared with cases of breast carcinoma as a whole. Male breast cancer reacts effectively to endocrine therapy because of a high frequency of hormone receptor expression.The aim of the present study was the assessment of correlations between stage, grade, expression of steroid receptors, basal/mesenchymal markers and proliferation index, as well as analysis of the impact of the above-mentioned parameters on overall (OS) and disease-free survival (DFS) in the group of 32 male breast cancer patients, treated at the Centre of Oncology in Cracow.We showed the significant positive correlation between MIB-1 LI and tumor stage, and hormone receptors (ER or PgR) immunonegativity, and expression of EGFR, vimentin (p<0.05) and P-cadherin (the last at statistical border). The presence of any of basal or masenchymal markers correlated with a more advanced tumor stage. Moreover tumors without vimentin expression were characterised by lower MIB-1 LI and were more frequently EGFR immunonegative.We found that hormone receptor negativity, vimentin immunopositivity and high MIB-1 LI are significant independent indicators of poor OS and DFS for male breast cancer patients (p<0.05). Key words: male breast cancer, basal markers, mesenchymal markers, nodal status, hormonal receptorsMale breast cancer is a rare form of carcinoma with an incidence rate of approximately 0.5-1% compared with cases of breast carcinoma as a whole [1,2,3,4]. Its peak incidence is noted in the seventh decade of life [5,6,7]. The most significant risk factors are an increased concentration of estrogen and obesity, that are a result of estrogen overproduction, impaired metabolism, and disturbances in the concentration of estrogen and androgen (i.e. in Klinefelter's syndrome) as well as the use of estrogenes in prostate cancer treatment [6,8,9,10,11]. Other factors include alcoholism, liver cirrhosis, the presence of hereditary BRCA1 and BRCA2 gene mutations and exposure to ionizing radiation, the electromagnetic field and increased temperature [6,8,9,12,13,14,15,16,17].According to Anderson et al., male breast cancer is characterised by similar biological factors to those present in the female variant of the cancer [18]. However, these tumors are diagnosed in more advanced stages of the disease, are characterised by higher degree of differentiation (more frequently G1, G2 grade) and a lower mitotic index in comparison to female breast cancer [5,19]. There are also differences in the frequency of the expression of hormone receptors and growth factor receptors [19,20]. Besides, the prognosis for male breast cancer is worse [5,18,20,21]. A study by Baojiang et al. of 5-year survival rates of patients suffering from male breast carcinoma and female breast carcinoma produced the following results: 61.2% and 68.7% (DFS), and 75.% and 82.9% (OS), respectively [20].Male breast cancer has a higher (over 90%) hormone receptor expression and, as a consequence, reacts more effect...

show abstract

Male breast cancer: An update in diagnosis, treatment and molecular profiling

Cited by 51 publications

References 78 publications

Clinicopathologic Characteristics of Male Breast Cancer: A Report of 21 Cases in Radiotherapy Center of Hamedan, Iran

Clinicopathologic Characteristics of Male Breast Cancer: A Report of 21 Cases in Radiotherapy Center of Hamedan, Iran

Male Breast Cancer: Case Studies and Literature Review

The biological markers and results of treatment in male breast cancer patients. The Cracow experience.

Contact Info

Product

Resources

About